Ellen Capon (Drug Target Review)2023-11-13T14:00:59
Foxp3 alters chromatin architecture of regulatory T cells, meaning Foxp3 could become a target for therapies that modulate immunosuppression.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-13T07:00:00Z
Contributor Dr Panos Roussos, Drug Target Review
2023-11-24T12:06:45
Sponsored by Quantum-Si
2026-08-11T07:02:00
Contributor Professor Joseph C. Wu, Drug Target Review
2026-08-26T07:00:00
Contributor Professor Paul O’Reilly, Drug Target Review
2026-10-28T14:00:00
Sponsored by Miltenyi Biotec
2023-03-20T13:41:33
Sponsored by Bio-Techne
2024-01-09T10:09:08
Sponsored by Sartorius iQue®
Site powered by Webvision Cloud